Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms.

ABSTRACT:

SUBMITTER: Orliaguet M 

PROVIDER: S-EPMC9176112 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature